drugset / Trial / NCT00298896

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

NCT00298896

Phase 2 Completed 55 enrolled Sunesis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).

Timeline

Start
2006-02
Primary completion
2007-08
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Vosaroxin Small molecule 48 mg/m2 Intravenous